Failure of natalizumab to prevent relapses in neuromyelitis optica. - Wikidata - wikimedia - TriplyDB

Failure of natalizumab to prevent relapses in neuromyelitis optica.

Failure of natalizumab to prevent relapses in neuromyelitis optica.

http://www.wikidata.org/entity/Q51360354

about

Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab Th17 Cells Pathways in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders: Pathophysiological and Therapeutic Implications Therapy of NMO spectrum disorders Ultrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease management International consensus diagnostic criteria for neuromyelitis optica spectrum disorders Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigms Immunology of neuromyelitis optica: a T cell-B cell collaboration Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Optic neuritis in neuromyelitis optica.Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.[Ultrahigh field MRI in context of neurological diseases].Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder Systemic Lupus Erythematosus (SLE) Complicated by Neuromyelitis Optica (NMO - Devic's Disease): Clinic-Pathological Report and Review of the Literature.Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.Differential diagnosis of neuromyelitis optica spectrum disorders.The treatment of neuromyelitis optica.The frequency of anti-aquaporin-4 Ig g antibody in neuromyelitis optica and its spectrum disorders at a single tertiary referral center in malaysia.Optical Coherence Tomography Reveals Distinct Patterns of Retinal Damage in Neuromyelitis Optica and Multiple Sclerosis.Epithelial V-like antigen mediates efficacy of anti-alpha₄ integrin treatment in a mouse model of multiple sclerosis CD19 as a molecular target in CNS autoimmunity.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica B lymphocytes in neuromyelitis optica The Correlation between Aquaporin-4 Antibody and the Visual Function of Patients with Demyelinating Optic Neuritis at Onset.The role of anti-aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica.Current options for the treatment of optic neuritis.Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder Epigallocatechin-3-gallate: a useful, effective and safe clinical approach for targeted prevention and individualised treatment of neurological diseases?Status of diagnostic approaches to AQP4-IgG seronegative NMO and NMO/MS overlap syndromes.Evaluation of aquaporin-4 antibody assays.Treatment of Neuromyelitis Optica: Review and Recommendations.Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab.

P2860

Q24598109-8183772A-1042-4D38-B811-7384165F361B Q26768649-CA0F90B4-E094-4617-8831-1F51DD8BE66C Q26779910-F582E824-7C0F-4978-BCB2-644F44E2A586 Q26796643-DB74075C-CFE5-4888-8D94-9A53F472FBA7 Q26824579-3F804290-7274-455A-BD7D-C54BD13BE3ED Q27006941-B1B91775-BA8C-461D-8D81-83FF1100643C Q27016045-FEE7D946-EA8A-4F46-A9A0-D56519E57799 Q28245749-4CDBE74C-261D-4742-8754-10C79B3874A9 Q28647496-00D7048B-79F7-4894-85BA-21125ED04628 Q28728565-525DFAA5-4172-4298-AA00-9A5D9557FA45 Q30371412-286154CB-9BDC-49E6-9B07-6CFDB41E7430 Q30577078-9CDE3763-D42E-4910-BFDF-EC0E7C7DC90B Q30610471-2337BD78-565E-4718-B092-8854F5764DD7 Q30649660-7C32F459-EBDB-408E-B4C8-5130A6EC0FB5 Q30676331-8493A26D-3B75-471E-A045-7C843AF7D5DE Q30699740-DDF83504-3BEC-4F53-B250-D264652FE488 Q30759627-5204486B-296A-45A0-9177-5BCD7D53A4E7 Q30785267-98D64BA2-B060-4A0D-8571-E81A30F97B73 Q33678297-499CB725-BA46-4245-8C01-FB85BEC5D3EE Q33734731-6E9FFC8E-4BA0-437B-BF5A-177F739F5BE5 Q33808279-4938D422-B11D-4A10-B162-4ADDF3DC44FC Q33812063-FABB6258-16B8-44B6-823F-7A8A1C0C6227 Q34399291-878EE893-6227-4997-BD28-23964F7FD644 Q34762744-DA0C2675-24BF-44C5-9F66-85E520E2CCDB Q34785270-9921D97B-551F-4F28-A54C-30B6F1EBBBC3 Q34948175-1CEC3882-E392-49FE-8C9E-1E233ABF2506 Q34976749-F1DEB7BA-821A-4A2D-9F39-1F9F59662B2F Q35052199-68E04E30-F99B-498A-8D39-C114C494A161 Q35067939-FCDC6435-A4D0-444A-90B4-2F95AA03B58F Q35591039-F3EDA920-6189-4171-8589-0B3156F27B13 Q35640735-C5BAC68E-9878-482D-8294-C89C05352269 Q36171516-E353A7DF-A26F-45C7-B44F-78BD84DCF50A Q36173222-55C1FD7D-BA2C-4FC2-A8E9-8229D83A2214 Q36484394-A82DD17E-A4EF-4251-A050-6DF6DDB929C2 Q36490876-5E9FB808-2C6C-45BF-A460-25B766EBA8B4 Q36648907-91767F99-1519-4798-ABD8-1451B5616AF5 Q36753462-60CD5207-98E7-4D77-ACB8-BE6B14F7D52C Q37404328-D76543F6-D39E-48F9-BDEE-F4B6D8C20434 Q37588037-9419840C-A825-4C10-BF0C-FF8EB646D5BA Q37684228-3FBEE778-C076-48A9-B1CD-DD3AA56E5783

P2860

Failure of natalizumab to prevent relapses in neuromyelitis optica.

http://www.wikidata.org/entity/Q51360354

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@en

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@nl

type

label

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@en

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@nl

prefLabel

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@en

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@nl

P1433

Q51360354-1C6BE4A9-2FF1-4B38-BDD2-B9AB4F804E2F

P1476

Q51360354-35AA2605-D49F-4F0A-AB06-43978991FA9F

P2093

Q51360354-0EB16093-B353-42DF-AA15-768EC90F120C

Q51360354-1AEE408A-4485-4062-BA20-F97E1C167F38

Q51360354-63AA6BAF-B325-46C7-9623-E3F718857F13

Q51360354-6F6AF8DC-B1BE-40DB-B3DD-E9CC18B23308

Q51360354-7F63CD75-0282-408E-90A5-5F1C1B68D8AB

Q51360354-8E3C19EF-4E66-4617-A673-BD81CA277D7E

Q51360354-A35A150E-0201-4DCC-AB65-13327AD68AAA

P304

Q51360354-867B0AAF-27A8-4F2F-977B-74E35F7E180A

P31

Q51360354-A008A7D1-575B-466A-932F-75D18103533D

P356

Q51360354-EE84D58C-FE89-4FD0-9000-5D9BBCFA4CE8

P433

Q51360354-71C793A1-D5B9-4E80-99E3-35B2D1975E9C

P478

Q51360354-99E977A4-C88B-470C-9381-75275889DF50

P50

Q51360354-94ACDC29-CA30-47CD-9A93-46B2E6F71C38

Q51360354-A148C8C9-BD05-407D-A9F7-07BE7A654988

P577

Q51360354-BAC1C142-3A04-4A60-A81A-8CCC509FABF6

P5875

Q51360354-420DA63F-C0F5-41F2-A68D-469FDD0CD222

P698

Q51360354-00AD0E99-404F-4B43-A3F0-4E02F3AEF4D2

P356

ARCHNEUROL.2011.216

P1433

P1476

Failure of natalizumab to prevent relapses in neuromyelitis optica.

@en

P2093

Achim Berthele

http://www.w3.org/2001/XMLSchema#string

Ingo Kleiter

http://www.w3.org/2001/XMLSchema#string

Kerstin Hellwig

http://www.w3.org/2001/XMLSchema#string

Neuromyelitis Optica Study Group

http://www.w3.org/2001/XMLSchema#string

Orhan Aktas

http://www.w3.org/2001/XMLSchema#string

Ralf A Linker

http://www.w3.org/2001/XMLSchema#string

Tania Kümpfel

http://www.w3.org/2001/XMLSchema#string

P304

239-245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUROL.2011.216

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

Friedemann Paul

P577

2012-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221830398

http://www.w3.org/2001/XMLSchema#string

P698

22332191

http://www.w3.org/2001/XMLSchema#string